Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications

被引:1
|
作者
Sposito, Marco [1 ,2 ]
Eccher, Serena [1 ,2 ]
Pasqualin, Luca [1 ,2 ]
Scaglione, Ilaria Mariangela [1 ,2 ]
Avancini, Alice [1 ,3 ]
Tregnago, Daniela [1 ,2 ]
Trestini, Ilaria [4 ]
Insolda, Jessica [1 ,2 ]
Bonato, Adele [5 ]
Ugel, Stefano [6 ,7 ]
Derosa, Lisa [8 ,9 ]
Milella, Michele [1 ,2 ]
Pilotto, Sara [1 ,2 ]
Belluomini, Lorenzo [1 ,2 ]
机构
[1] Univ Verona Sch Med, Dept Engn Innovat Med DIMI, Sect Oncol, Verona, Italy
[2] Verona Univ Hosp Trust, Verona, Italy
[3] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy
[4] Univ & Hosp Trust AOUI Verona, Hosp Med Direct, Dietet Serv, Verona, Italy
[5] Santa Chiara Hosp, Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[6] Univ Verona, Univ Hosp, Immunol Sect, Verona, Italy
[7] Univ Verona, Dept Med, Verona, Italy
[8] INSERM U1015, Gustave Roussy Canc Campus, Villejuif, France
[9] Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France
关键词
Anaplastic lymphoma kinase; immunotherapy; non-small cell lung cancer; targeted therapy; tumor immune microenvironment; CD8(+) T-CELLS; PD-L1; EXPRESSION; PLUS NIVOLUMAB; OPEN-LABEL; IMMUNOTHERAPY; EFFICACY; SAFETY; HETEROGENEITY; CERITINIB; EGFR;
D O I
10.1080/1744666X.2024.2372327
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionApproximately 5% of non-small cell lung cancer (NSCLC), exhibits anaplastic lymphoma kinase (ALK) rearrangements. EML4-ALK fusions account for over 90% of ALK rearrangements in NSCLC. The advent of treatment targeting ALK has significantly improved survival rates in patients with advanced ALK-positive NSCLC. However, the emergence of resistance mechanisms and the subsequent progression disease inevitably occurs. The tumor immune microenvironment (TIME) plays a pivotal role in lung cancer, influencing disease development, patient's outcomes, and response to treatments.Areas coveredThe aim of this review is to provide a comprehensive characterization of the TIME in ALK rearranged NSCLC and its intrinsic plasticity under treatment pressure.Expert opinionRecognizing the fundamental role of the TIME in cancer progression has shifted the paradigm from a tumor cell-centric perspective to the understanding of a complex tumor ecosystem. Understanding the intricate dynamics of the TIME, its influence on treatment response, and the potential of immunotherapy in patients with ALK-positive NSCLC are currently among the primary research objectives in this patient population.
引用
收藏
页码:959 / 970
页数:12
相关论文
共 35 条
  • [1] Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
    Xia, Wenchao
    Yang, Jing
    Li, Hongbin
    Li, Ling
    Liu, Jinfeng
    GLOBAL MEDICAL GENETICS, 2024, 11 (02): : 175 - 186
  • [2] Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
    Lovly, Christine M.
    McDonald, Nerina T.
    Chen, Heidi
    Ortiz-Cuaran, Sandra
    Heukamp, Lukas C.
    Yan, Yingjun
    Florin, Alexandra
    Ozretic, Luka
    Lim, Diana
    Wang, Lu
    Chen, Zhao
    Chen, Xi
    Lu, Pengcheng
    Paik, Paul K.
    Shen, Ronglai
    Jin, Hailing
    Buettner, Reinhard
    Ansen, Sascha
    Perner, Sven
    Brockmann, Michael
    Bos, Marc
    Wolf, Juergen
    Gardizi, Masyar
    Wright, Gavin M.
    Solomon, Benjamin
    Russell, Prudence A.
    Rogers, Toni-Maree
    Suehara, Yoshiyuki
    Red-Brewer, Monica
    Tieu, Rudy
    de Stanchina, Elisa
    Wang, Qingguo
    Zhao, Zhongming
    Johnson, David H.
    Horn, Leora
    Wong, Kwok-Kin
    Thomas, Roman K.
    Ladanyi, Marc
    Pao, William
    NATURE MEDICINE, 2014, 20 (09) : 1027 - 1034
  • [4] Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment
    Irene van der Haar Àvila
    Britt Windhouwer
    Sandra J. van Vliet
    Cancer and Metastasis Reviews, 2023, 42 : 941 - 958
  • [5] Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment
    Avila, Irene van der Haar
    Windhouwer, Britt
    van Vliet, Sandra J. J.
    CANCER AND METASTASIS REVIEWS, 2023, 42 (03) : 941 - 958
  • [6] Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
    Khaddar, Satvik
    Kapoor, Akhil
    Noronha, Vanita
    Patil, Vijay M.
    Menon, Nandini
    Mahajan, Abhishek
    Janu, Amit
    Kumar, Rajiv
    Purandare, Nilendu
    Prabhash, Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2022, 11 (03) : 243 - 248
  • [7] Assessing the Prognostic Significance of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A retrospective study
    Hua, Su Yu
    Cheng, Wen-Chien
    Tu, Chih-Yen
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [8] Clinicopathological features and diagnostic methods of ALK fusion-positive non-small cell lung cancer in Korea
    Chang, Won Chul
    Kim, Han Kyeom
    Shin, Bong Kyung
    ONCOLOGY REPORTS, 2020, 43 (01) : 218 - 228
  • [9] Large-scale transcriptomic profiling of the tumor immune microenvironment in ALK plus lung cancer
    Lam, Vincent K.
    Balan, Archana
    Zhu, Qingfeng
    Murray, Joseph Christopher
    Marrone, Kristen A.
    Scott, Susan Combs
    Feliciano, Josephine Louella
    Hann, Christine L.
    Ettinger, David S.
    Smith, Kellie Nicole
    Forde, Patrick M.
    Brahmer, Julie R.
    Levy, Benjamin Philip
    Elliott, Andrew
    VanderWalde, Ari
    Oberley, Matthew James
    Liu, Stephen V.
    Ma, Patrick C.
    Anders, Robert A.
    Anagnostou, Valsamo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] A Study on Clinicopathological Features and Diagnostic Methods of ALK Fusion-Positive Non-Small Cell Lung Cancer in KR
    Shin, B. K.
    Chang, W. C.
    Kim, H. K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1146 - S1146